Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$73.30 USD

73.30
7,219,345

+1.66 (2.32%)

Updated Jul 17, 2024 04:00 PM ET

After-Market: $73.43 +0.13 (0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Gilead Sciences (GILD) Stock Moves -0.51%: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $62.34, marking a -0.51% move from the previous day.

VERU's Shares Jump on Successful COVID-19 Study Results

VERU gains on the success of its late stage study evaluating the efficacy and safety of oral sabizabulin 9 mg for COVID-19.

Zacks Market Edge Highlights: ExxonMobil, Chevron, Philip Morris International, Gilead Sciences and General Mills

ExxonMobil, Chevron, Philip Morris International, Gilead Sciences and General Mills are part of Zacks Market Edge blog.

Tracey Ryniec headshot

Q2 Earnings: Energy and What Else?

Expectations are low for this earnings season. Will companies surprise the Street?

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $62.34, moving -0.03% from the previous trading session.

Should You Invest in the iShares Biotechnology ETF (IBB)?

Sector ETF report for IBB

Pfizer (PFE) Seeks FDA Nod for Its Oral Antiviral COVID Pill

Pfizer (PFE) submits NDA to the FDA seeking approval for using its oral antiviral COVID pill in vaccinated and unvaccinated patients at a high risk of developing severe COVID-19 complications.

Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & More

Regulatory and other updates from Epizyme (MRNA) and Kezar (KZR) are a few key highlights from the biotech sector during the past week.

Gilead's (GILD) Yescarta Gets EC Nod for Follicular Lymphoma

Gilead's (GILD) cell therapy, Yescarta, gets approval in Europe for a third indication- adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.

Gilead Sciences (GILD) Stock Moves -0.99%: What You Should Know

Gilead Sciences (GILD) closed at $62.21 in the latest trading session, marking a -0.99% move from the prior day.

Gilead (GILD) Resubmits NDA for HIV Inhibitor to the FDA

Gilead (GILD) announces the resubmission of the NDA for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in the United States.

Gilead (GILD) HIV Candidate Gets Positive CHMP Recommendation

Gileads (GILD) lenacapavir gets a positive CHMP opinion for the treatment of HIV-1 infection.

Bristol Myers (BMY) Breyanzi Gets FDA Nod for Label Expansion

Bristol Myers' CAR T cell therapy Breyanzi was approved by the FDA for relapsed or refractory large B-cell Lymphoma after one prior therapy.

Gilead (GILD) Announces Positive Data on Hepcludex for HDV

Gilead (GILD) Hepcludex meets the primary endpoint in a phase III study for the treatment of chronic hepatitis delta virus (HDV) infection at 48 weeks.

Sheraz Mian headshot

Top Stock Reports for Tesla, Broadcom & Anthem

Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), Broadcom Inc. (AVGO), and Anthem, Inc. (ANTM).

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $61.51, moving +1.65% from the previous trading session.

Gilead Sciences (GILD) Stock Moves -1.15%: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $57.72, marking a -1.15% move from the previous day.

Pfizer (PFE) COVID Pill Ineffective in Standard Risk Patients

Pfizer (PFE) stops enrolling patients in a phase II/III study evaluating its COVID pill in standard-risk population after new data from this study showed that it is not all statistically significant.

Gilead Sciences (GILD) Stock Moves -0.72%: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $60.74, moving -0.72% from the previous trading session.

Why Is Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biogen Inc. (BIIB) Down 4.8% Since Last Earnings Report: Can It Rebound?

Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Novartis (NVS) Wins FDA Nod for Label Expansion of Kymriah

Novartis' (NVS) CAR-T cell therapy Kymriah (tisagenlecleucel) gets an FDA approval for a third indication.

The Zacks Analyst Blog Highlights JPMorgan Chase, Gilead Sciences, CSX, CVS Health and China Petroleum & Chemical

JPMorgan Chase, Gilead Sciences, CSX, CVS Health and China Petroleum & Chemical have been included in this Analyst Blog.

Mark Vickery headshot

Top Research Reports for JPMorgan, Gilead Sciences & CSX

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Gilead Sciences, Inc. (GILD) and CSX Corporation (CSX).

Biotech Stock Roundup: BBIO Up on BMY Deal, GILD & CMRX Offer Updates

Regulatory updates and acquisition news from Bristol Myers' (BMY) and BridgeBio Pharma (BBIO) are a few key highlights from the biotech sector during the past week.